2P4 Stock Overview An in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for BioPorto Historical stock prices Current Share Price DKK 0.20 52 Week High DKK 0.34 52 Week Low DKK 0.15 Beta 1.17 1 Month Change -3.70% 3 Month Change -19.59% 1 Year Change -30.48% 3 Year Change -33.45% 5 Year Change -51.25% Change since IPO -53.79%
Recent News & Updates BioPorto A/S to Report Q3, 2025 Results on Nov 19, 2025
Bioporto A/S Maintains Revenue Guidance for the Year 2024 Nov 14
BioPorto A/S Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL) for Adult Use at Massachusetts General Hospital Oct 29
Second quarter 2024 earnings released: kr.0.04 loss per share (vs kr.0.058 loss in 2Q 2023) Aug 16
Bioporto A/S Affirms Earnings Guidance for 2024 Aug 15
New minor risk - Shareholder dilution Jun 25 See more updates BioPorto A/S to Report Q3, 2025 Results on Nov 19, 2025
Bioporto A/S Maintains Revenue Guidance for the Year 2024 Nov 14
BioPorto A/S Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL) for Adult Use at Massachusetts General Hospital Oct 29
Second quarter 2024 earnings released: kr.0.04 loss per share (vs kr.0.058 loss in 2Q 2023) Aug 16
Bioporto A/S Affirms Earnings Guidance for 2024 Aug 15
New minor risk - Shareholder dilution Jun 25 BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024
Bioporto A/S Provides Revenue Guidance for 2024 May 09
First quarter 2024 earnings released: kr.0.04 loss per share (vs kr.0.048 loss in 1Q 2023) May 08
Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024 Apr 10
Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election Apr 05
Full year 2023 earnings released: kr.0.16 loss per share (vs kr.0.24 loss in FY 2022) Apr 04
BioPorto A/S Announces CEO Changes Jan 10 BioPorto A/S to Report Nine Months, 2024 Results on Oct 30, 2024
BioPorto A/S, Annual General Meeting, Apr 30, 2024 Dec 16
BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States Dec 08
BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member Dec 05
Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023 Nov 01
Bioporto A/S Announces Resignation of Neil Goldman as CFO Sep 20
New major risk - Share price stability Aug 09 BioPorto A/S announced that it has received $0.11 million in funding Aug 02
Second quarter 2023 earnings released: kr.0.06 loss per share (vs kr.0.05 loss in 2Q 2022) Aug 02
BioPorto A/S Maintains Earnings Guidance for the Year 2023 Aug 01
New minor risk - Shareholder dilution Jun 25
High number of new and inexperienced directors May 18
First quarter 2023 earnings released: kr.0.05 loss per share (vs kr.0.06 loss in 1Q 2022) May 11
BioPorto A/S Maintains Financial Guidance for 2023 May 11
Full year 2022 earnings released: kr.0.24 loss per share (vs kr.0.21 loss in FY 2021) Mar 31 BioPorto A/S to Report Q1, 2023 Results on May 10, 2023
BioPorto A/S Appoints Nis Kruse as EVP of Strategic Partnerships and Gm of EMEA & Apac Dec 06
Less than half of directors are independent Nov 16
Third quarter 2022 earnings released Nov 11
BioPorto A/S Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration Nov 11
BioPorto A/S Revises Earnings Guidance for the Year 2022 Nov 10
BioPorto A/S Revises Earnings Guidance for the Year 2022 Aug 19
Second quarter 2022 earnings released Aug 18
BioPorto A/S Revises Earnings Guidance for the Year 2022 Aug 17
BioPorto A/S Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S Jun 29 BioPorto A/S Appoints Dr. Prasad Devarajan as New Senior Medical Director Jun 21
BioPorto A/S Maintains its Earnings Guidance for the Year 2022 May 12
Less than half of directors are independent May 02
Full year 2021 earnings released: kr.0.21 loss per share (vs kr.0.30 loss in FY 2020) Apr 07 BioPorto A/S Provides Earnings Guidance for the Full Year 2022 Mar 10
Third quarter 2021 earnings released: kr.0.04 loss per share (vs kr.0.087 loss in 3Q 2020) Nov 18
Second quarter 2021 earnings released: kr.0.051 loss per share (vs kr.0.077 loss in 2Q 2020) Aug 21
BioPorto A/S Maintains Earnings Guidance for the Year 2021 Aug 20
BioPorto A/S Provides Pipeline Update Regarding COVID-19 Test Jun 30
First quarter 2021 earnings released: kr.0.06 loss per share (vs kr.0.088 loss in 1Q 2020) May 13
BioPorto A/S Provides Earning Guidance for the Year 2021 May 12
Independent Vice Chairman Torben Nielsen has left the company May 06
Independent Director has left the company May 06
Full year 2020 earnings released: kr.0.30 loss per share (vs kr.0.41 loss in FY 2019) Mar 19
Bioporto A/S Provides Earnings Guidance for the Year 2021 Mar 18
BioPorto Provides Pipeline Update Mar 05
New 90-day high: €0.66 Jan 04
Revenue misses expectations Nov 19
Third quarter 2020 earnings released: kr.0.09 loss per share Nov 19 BioPorto A/S, Annual General Meeting, Apr 29, 2021
BioPorto A/S has completed a Follow-on Equity Offering in the amount of DKK 106.632762 million. Oct 16
BioPorto A/S Plans Initial Clinical Evaluation of Grad-Based Test for Rapid Detection of COVID-19 Virus Sep 18
New 90-day low - €0.28 Sep 10
Earnings released Aug 20
New 90-day low - €0.30 Aug 12 Shareholder Returns 2P4 DE Biotechs DE Market 7D -9.7% -2.5% -2.6% 1Y -30.5% -14.2% 7.1%
See full shareholder returns
Return vs Market: 2P4 underperformed the German Market which returned 8% over the past year.
Price Volatility Is 2P4's price volatile compared to industry and market? 2P4 volatility 2P4 Average Weekly Movement 8.3% Biotechs Industry Average Movement 6.7% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: 2P4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2P4's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company BioPorto A/S, an in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated clinical chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. BioPorto A/S was incorporated in 1917 and is based in Hellerup, Denmark.
Show more BioPorto A/S Fundamentals Summary How do BioPorto's earnings and revenue compare to its market cap? 2P4 fundamental statistics Market cap €91.69m Earnings (TTM ) -€8.22m Revenue (TTM ) €4.68m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2P4 income statement (TTM ) Revenue DKK 34.91m Cost of Revenue DKK 10.05m Gross Profit DKK 24.86m Other Expenses DKK 86.16m Earnings -DKK 61.30m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 20, 2025
Earnings per share (EPS) -0.14 Gross Margin 71.22% Net Profit Margin -175.62% Debt/Equity Ratio 0%
How did 2P4 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/19 06:29 End of Day Share Price 2024/12/19 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources BioPorto A/S is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution null null Brookline Capital Markets Jyoti Prakash Edison Investment Research Yi Chen H.C. Wainwright & Co.
Show 0 more analysts 
